The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial.
Saved in:
| Title: | The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. |
|---|---|
| Authors: | Patel NR; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden.; Division of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess Hospital, Boston, MA., Cunoosamy DM; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Fagerås M; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Taib Z; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Asimus S; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Hegelund-Myrbäck T; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Lundin S; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Pardali K; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Kurian N; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Ersdal E; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Kristensson C; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Korsback K; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Palmér R; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden., Brown MN; Innovative Medicines and Early Development, AstraZeneca, Boston, MA, USA., Greenaway S; Quintiles Drug Research Unit at Guy's Hospital, London., Siew L; Quintiles Drug Research Unit at Guy's Hospital, London., Clarke GW; Quintiles Drug Research Unit at Guy's Hospital, London.; Department of Cardiothoracic Pharmacology, NHLI, Imperial College London, London, UK., Rennard SI; Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska, Omaha, NE, USA.; Clinical Discovery Unit, Innovative Medicines and Early Development, AstraZeneca, Cambridge, UK., Make BJ; Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Health, University of Colorado, Denver, CO., Wise RA; Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, MD, USA., Jansson P; Innovative Medicines and Early Development, AstraZeneca, Gothenburg, Sweden. |
| Source: | International journal of chronic obstructive pulmonary disease [Int J Chron Obstruct Pulmon Dis] 2018 Mar 27; Vol. 13, pp. 1009-1019. Date of Electronic Publication: 2018 Mar 27 (Print Publication: 2018). |
| Publication Type: | Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101273481 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2005 (Electronic) Linking ISSN: 11769106 NLM ISO Abbreviation: Int J Chron Obstruct Pulmon Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1178-2005 |
|---|---|
| DOI: | 10.2147/COPD.S150576 |
